Sequence Note

Rapid Spread and Genetic Diversification of HIV Type 1 Subtype C in a Rural Area of Southern Mozambique

MARIA LAHUERTA,1,* ESTER APARICIO,2,* AZUCENA BARDAJI,1,3 SANDRA MARCO,2 JAHIT SACARLAL,3,4 INACIO MANDOMANDO,3 PEDRO ALONSO,1,3 MIGUEL ANGEL MARTINEZ,2 CLARA MENENDEZ,1,3 and DENISE NANICHE 1

ABSTRACT

In this study, we analyzed the human immunodeficiency type 1 (HIV-1) viruses circulating between 1999 and 2004 in antiretroviral-naive women from a rural area of southern Mozambique. Nucleotide sequencing of the HIV-1 long terminal repeat (LTR) U3, envelope (env) C2V3C3, and protease (pr) genomic regions was performed from women sera samples collected in 1999 and 2004. Phylogenetic analysis revealed that all amplified sequences belonged to subtype C. Although env sequences were predominantly CCR5-tropic (R5), CXCR4-tropic (X4) variants were also identified (13%). Both 1999 and 2004 sequences were widely dispersed across multiple clusters and were related to different reference sequences from neighboring countries. Sequences from 2004 showed significantly more nucleotide genetic diversity than sequences from 1999. Importantly, genetic diversification was also observed at the pr and env amino acid level, suggesting that positive selection forces were implicated in the viral diversification. These results indicate the rapid spread and diversification of subtype C virus in Mozambique where HIV-1 prevalence in the Manhiça antenatal clinic reached 23% in 2004.

INTRODUCTION

Sub-Saharan Africa is the region most severely affected by HIV-1, with 24.7 million (60%) of the 39.5 million people living with HIV/AIDS.1 This region is characterized by the circulation of several genotypes and circulating recombinant forms (CRFs).2 However, subtype C viruses are rapidly spreading in southern Africa and becoming the predominant variant of the epidemic, accounting for more than 56% of all global infections.3,4 There is evidence that suggests that different subtypes may have distinct biological features that may have an impact on transmissibility and on disease progression.5,6 The high genetic variability of HIV-1 and its potential for recombination are clearly important to escape from the immune system and also play a major role in the development of resistance to highly active antiretroviral therapy (HAART).7,8

There has been tremendous development of new antiretroviral drugs for the treatment of HIV-1 subtype B viruses, but information on their efficacy in nonsubtype B viruses is scarce. Recently, the genetic characterization of the protease and reverse transcriptase genes from non-B subtypes has revealed that minor mutations are often present in natural variants.9–11 However, it is unknown whether the presence of these polymorphisms facilitates the generation of resistance during treatment with protease inhibitors (PI).12

Although Mozambique is ranked as having the tenth highest HIV-1 prevalence in the world, relatively little information on the molecular epidemiology of HIV-1 in Mozambique is avail-

1Barcelona Center for International Health Research (CRESIB), Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
2Fundació irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain.
3The Manhiça Health Research Center (CISM), Manhiça, Mozambique.
4Faculdade de Medicina da Universidade Eduardo Mondlane, Maputo, Mozambique.
*Both authors contributed equally to this study.
able. Mozambique suffered a long civil war until 1992, and since then, the spread of HIV-1 has been increasing rapidly, with a shift in overall reported prevalence from 8.2% in 1998 to 16.2% in 2004.13 The number of people living with HIV-1 is estimated to be approximately 1.8 (1.4–2.2) million, with women representing up to 58% of those infected.1 In Mozambique, it is estimated that only 3.4% of pregnant women who need antiretroviral therapy (ART) for prevention of mother-to-child transmission actually receive it. Furthermore, of those HIV-1-infected adults in Mozambique who require HAART, only approximately 9% receive treatment.1

To date, there are only two published studies assessing both HIV-1 subtypes and genetic diversity in Mozambique. One study evaluated drug resistance in drug-naïve HIV-1 patients in two hospitals near Maputo,14 The second study performed genetic characterization of HIV-1 circulating in Beira, a central region of the country.15 Both studies determined that subtype C was the dominant HIV-1 subtype. However, in Mozambique longitudinal studies analyzing HIV-1 genetic diversification and evolution are lacking. Large-scale implementation of HAART has begun in many southern and eastern African countries, including Mozambique. Therefore, studies including phylogenetic analysis, drug resistance polymorphisms, genetic diversity, and molecular evolution of HIV-1 may improve the treatment success in this area.

To gain a better understanding of genetic diversity, molecular evolution and epidemiological patterns of HIV-1 spread, and drug resistance polymorphisms, we studied regions in the HIV U3 long terminal repeat (LTR), the envelope (env) C2V3C3 and protease (pr) gene. This study focused on HIV-1 sequences obtained in 1999 and in 2004, from women living in a semi-rural area of southern Mozambique.

MATERIALS AND METHODS

Study area and population

The study was undertaken at the Centro de Investigação em Saúde da Manhiça (CISM) in Manhiça District, southern Mozambique. Blood samples were obtained from HIV-positive women at the time of recruitment from two different studies performed in 1999 and 2004.16,17 After obtaining informed consent, blood samples were collected in EDTA anticoagulant tubes and plasma was stored at − 80°C until analyzed. HIV-1 disease status was not available for these women. Since HAART was not available in Manhiça during these studies, all women were considered to be drug naïve at recruitment. The 1999 study included 300 women, of whom 30 were HIV−, aged 14–61 years and attending antenatal and family planning clinics. The 2004 study included 1030 pregnant women attending the antenatal clinic of whom 207 were HIV−. Both studies were approved by the Ethics Review Board of Mozambique and Hospital Clinic of Barcelona.

PCR amplification and sequencing

Extraction of viral RNA from the 1999 plasma samples was performed using the Qiump viral RNA mini kit (Qiagen) and viral load was determined using the Cobas Amplicor HIV-1 Monitor Test v1.5 (Roche Diagnostics). For the 2004 samples, viral load was determined using the Amplicor HIV-1 Monitor Test v1.5 (Roche Diagnostics) and due to the small volume of samples, RNA extracted during this process was reverse transcribed to cDNA with Superscript II and random hexamer primers (Invitrogen). The RNA template and random primers (300 ng) were heated to 65°C for 10 min, chilled on ice, and reverse transcribed in a 20 µl reaction volume containing 1 × reaction buffer, 109 mM dithiothreitol, 0.5 mM each deoxyribonucleoside triphosphate, and 200 U of Superscript reverse transcriptase (Invitrogen) at 37°C for 1 h, followed by 15 min at 95°C. The cDNA was shipped to Fundación Irsi-Caixa (Barcelona, Spain) where amplification and sequencing were performed.

Amplification of the U3 LTR, env C2V3C3 region, and pr was performed for the 1999 and 2004 samples. The LTR and env C2V3C3 regions were amplified following the reaction conditions and primers described in Ibanez et al. and Tapia et al., respectively.18,19 LTR primers used for first-round amplification were NI25 (HXB2 positions 57–77) and NI23 (HXB2 positions 389–408) and for second-round amplification were NI33 (HXB2 positions 350–372) and NI35 (HXB2 positions 81–100). The outer pair of primers for env amplification were ENV1 (HXB2 positions 6888–6878) and ENV4 (HXB2 positions 7520–7539) and the inner primers were ENV2 (HXB2 positions 6885–6904) and ENV3 (HXB2 positions 7365–7385). The pr region was amplified from the cDNA with SPROT1 (5’-ATTTTTTA GGGAARATYGGCCCT-3’; positions 2084–2106) and SPROT1 (5’-YGGAGTR TTRATGGAATTTT- CAGG-3’; positions 2703–2727) as outer primers and SPROT2 (5’-ATTTTTTAGGGAARATYGGCCCT-3’; positions 2118–2140) and SPROT2 (5’-CTTTATTTTTCTTCTGTYAA- TGG-3’; positions 2622–2646) as inner primers. The following amplification conditions were used for the first-round and nested polymerase chain reaction (PCR): 2 min at 95°C, followed by 35 cycles of 30 s at 95°C, 30 s at 55°C, 40 s at 72°C, and a final extension step at 72°C for 7 min.

Both strands of the PCR fragments were purified with Exo-SAP-IT (Applied Biosystems) and sequenced directly using internal (nested) PCR primers and the ABI Prism Dye Terminator Cycle Sequencing Reaction kit (Perkin Elmer). The products of the reactions were then analyzed on an ABI Prism 3100 sequencer (Perkin Elmer). Sequence editing was performed using the program SEQUENCER, version 4.6 (GeneCodes).

Subtyping and phylogenetic analysis

The new sequences were manually edited with BioEdit version 7 and compared to subtype reference strains downloaded from the Los Alamos subtype database (http://hiv-web.lanl.gov/content/hiv-db/SUBTYPE_REF/align.html). To examine intrasubtype variations, a subset of subtype C from neighboring countries was downloaded from the Los Alamos BLAST search database (http://hiv-web.lanl.gov). Multiple alignments were performed with Clustal W 1.7.30 Sequence and phylogenetic analyses were performed as previously described.21,22 Briefly, phylogenetic trees were created with PAUP* version 4.0b 10 with likelihood settings by selecting the best-fitting evolutionary models with the Akaike identification system, implemented in Modeltest 3.6.23,24 The TVM+I+G model was used
for LTR, the GTR+I+G model for the protease region, and the
K81uf+I+G for the envelope region. The robustness of the
trees was evaluated by bootstrap analysis with 1000 rounds of
replication. Trees were viewed with Treeview.25 The sequence
ID used to name the study sequences is the ID number used in
the CISM to track samples, while the sequence ID for the
reference strains has been simplified with the initials of the
country.

Mean genetic distances were measured with the corre-
spanding model for each region implemented in PAUP* ver-
sion 4.0b.23 SNAP (http://hiv-web.lanl.gov) was used to
calculate the synonymous-to-nsynonymous substitution
ratio.26,27 The V3 loop amino acid sequences were intro-
duced into the WebPSSM program (http://ubik.microbiol.
washington.edu/computing/pssm) to determine the corecep-
tor usage, depending on its net charge and the polarity of
the amino acids located at positions 11 and 25.31 A lower
V3 net charge facilitates a tighter interaction of gp120 with
CCR5 while a higher V3 net charge facilitates the interac-
tion with CXCR4.32

Drug resistance genotyping

The Stanford University HIV Drug Resistance database (alg
Program) (http://hivdb.stanford.edu) was used to determine re-
sistance-associated mutations and polymorphisms present in
the protease (1999 and 2004 sequences). Known mutations and/or
polymorphisms were assessed in the protease sequences from
1999 (n = 20) and from 2004 (n = 31).

Statistical analyses

The nonparametric Mann–Whitney test was used to test for
differences between intrasubtype genetic distances, synonym-
ous and nonsynonymous mutations, and distance to ancestor
between 1999 and 2004 sequences. A p value lower than 0.05
was considered statistically significant. Analyses were per-
formed using the Graph Pad software package, version 4
(GraphPad Software, Inc.).

RESULTS

Characteristics of the study population

Manhiça district, a semirural area of southern Mozambique,
has an estimated population of 36,000 inhabitants under
demographic surveillance prior to 2004. The prevalence of
HIV-1 infection in pregnant women attending the antenatal
clinic was 12% in 1999 and 23% in 2004.16,17 Both in 1999
and 2004, the two populations were women, with a median age
of 33 (IQR 25–48) and 23 (IQR 20–30) years, respectively. All
women from the 2004 study and 60% of women from the 1999
study were pregnant at the time of sample collection. The two
groups had similar viral load levels, with median values of
12,200 copies/ml (IQR 3650–36,100) for the 1999 study pop-
ulation and 18,620 (IQR 10,388–49,091) copies/ml for the 2004
study population (p = 0.11).

Subtyping and phylogenetic analysis

To subtype and determine the phylogenetic relationships be-
tween sequences, the LTR, env, and pr regions were amplified
from available sera samples collected in 1999 and 2004. Of the
30 HIV+ blood samples available from 1999, amplification was
successfully performed for LTR (n = 21), env (n = 18), and pr
(n = 20). Of the 207 HIV+ women in the 2004 study, 51 were
randomly chosen for this study. Due to small quantities of cDNA,
out of the 51 samples available from 2004, amplification was per-
fomed for LTR (n = 37), env (n = 32), and pr (n = 31).

Phylogenetic analysis showed that all sequences from LTR, env,
and pr clustered into the subtype C clade (data not shown). To in-
vestigate within-subtype C clustering, phylogenetic trees were con-
structed with published LTR, envelope, and protease C sequences
from central Mozambique and several sequences from nine dif-
ferent African neighboring countries (South Africa, Zimbabwe,
Tanzania, Malawi, Ethiopia, Kenya, Botswana, Somalia, and Gene-
gal) from the sequences available at the Los Alamos HIV sequence
database (http://www.hiv.lanl.gov/components/hiv-db/combined_-
search_s_tree/search.html).

Both 1999 and 2004 envelope sequences from Manhiça were
widely dispersed across multiple clusters (Fig. 1A). Similar tree
topologies were obtained for LTR and protease (Fig. 1B and
C), although the envelope tree tended to have higher bootstrap
values reflecting a higher robustness of the clusters.

Different phylogenetic associations were observed with other
subtype C sequences from neighboring countries. However, dis-
tance matrix-based phylogenetic analysis did not reveal poten-
tial clusters and couples of genetically related sequences (boot-
strap values higher than 70%) between our sequences and any
of the reference sequences from neighboring countries. Distinct
sublineages consisting only of closely related Mozambican se-
quences from 1999 and 2004 with bootstrap values higher than
70% were identified in LTR, envelope, and protease, suggesting
an epidemiological link between these samples (marked
with brackets in Fig 1).

Genetic divergence and selection pressure

To assess the intrasubtype genetic diversity, the genetic dis-
tances between each set of sequences were calculated. Signifi-
cantly higher median genetic distances were observed for se-
quencies from 2004 as compared to sequences from 1999 in all
regions assessed: LTR, env, and pr (Table 1). Larger median
genetic distances reflecting increased genetic diversity were
most pronounced in the envelope region.

Sequences were compared to assess the mutational pattern
of protease and envelope in the absence of drug therapy (Table
1). Both genes were found to be under purifying (negative) se-
lection pressure with a ratio of ds/dn greater than 1. The aver-
age ds/dn for both 1999 and 2004 sequences was 1.979 and
2.047 for the envelope region and 6.123 and 7.196 for the pro-
tease region, respectively. Protease showed very low rates of
nonsynonymous mutations reflecting different pressure con-
straints between pr and env genes.

Coreceptor usage determined by V3 loop sequences

The average net charge in this group of sequences was +4.3.
The characteristic GPGQ crown found in most non-B subtypes
FIG. 1. (A) Envelope sequences from Manhiça (both 1999 and 2004) were widely dispersed across multiple clusters. Similar tree topologies were obtained for LTR (B) and protease (C).
FIG. 1. (Continued).
was conserved in 98% (49/50) of the samples. According to the sequence analysis with WebPSSM, 88% (44/50) of the viruses potentially used CCR5, with six sequences reflecting potential R5X4 or X4 receptor usage (three from 1999 and three from 2004). Although these results indicated a predominance of R5 viruses, they also showed that potential X4 receptor usage is not prohibited in subtype C envelope regions.

Mutations associated with drug resistance to protease inhibitors

No primary resistance mutations to protease inhibitors were detected in any of the 51 samples. However, a high prevalence of minor mutations was observed at the following positions: K20R (21.6%), M36I (74.5%), L63P (27.5%), and I93L (94.1%). Other polymorphisms present at lower frequency are reported in Table 2.

**DISCUSSION**

Despite the high prevalence of HIV-1 in Mozambique, so far only two studies have examined the genetic diversity of Mozambican HIV-1 viruses.14,15 Thus, the aim of this study was to characterize the HIV-1 epidemic at a molecular level in women from a rural area of southern Mozambique and to assess viral genetic diversity in 1999 and in 2004.

Subtype analysis showed that all the LTR, envelope, and protease regions studied were subtype C, in accordance with other studies that found all HIV-1 isolates in Maputo, Mozambique to be subtype C and all but one to be subtype C in Beira.14,15 Overall, these results indicate that the HIV-1 epidemic in Mozambique is quite homogeneous with regard to subtype since it is composed almost exclusively of clade C viruses. This is similar to the situation found in neighboring countries such as South Africa, but different from countries such as Tanzania that also have A and D viruses circulating.19,33 Phylogenetic analyses revealed that Mozambican sequences did not form a country-specific cluster. Instead, sequences were randomly spread throughout the trees without showing different homology from other subtype C sequences from neighboring countries. The wide genetic variation of these sequences suggests multiple introductions of subtype C viruses in Mozambique and thus confirms the existence of multiple circulating clade C sublineages in southern Africa as described.34 Studies of population migrations suggest that HIV-1 introduction into Mozambique may have been associated with the frequent temporary labor migrations of adult males from southern Mozambique to South Africa.35

| Table 1. Genetic Distances, Ratio of Nonsynonymous to Synonymous Amino Acid Substitutions |
|---------------------------------------------|-----------------|-----------------|-----------------|
|                                           | 1999 sequences<sup>a</sup> | 2004 sequences<sup>b</sup> | p-value        |
| Genetic distances                          | Median       | SD           | Median       | SD           |       |
| LTR                                        | 0.1345      | 0.035       | 0.157       | 0.036       | 0.0085<sup>c</sup> |
| Protease                                   | 0.0664      | 0.0189      | 0.071       | 0.0179      | 0.0085<sup>c</sup> |
| Envelope                                   | 0.1805      | 0.046       | 0.2         | 0.037       | 0.0001<sup>c</sup> |
| Envelope Synonymous substitutions           | 0.2204      | 0.0583      | 0.2431      | 0.07626     | 0.0022<sup>c</sup> |
| Envelope Nonsynonymous substitutions        | 0.115       | 0.02651     | 0.1236      | 0.02295     | 0.0001<sup>c</sup> |
| Envelope Ratio ds/dn                       | 1.979       | 0.589       | 2.047       | 0.7758      | 0.6855    |
| Protease Synonymous substitutions           | 0.1551      | 0.0431      | 0.1703      | 0.04397     | 0.0001<sup>c</sup> |
| Protease Nonsynonymous substitutions        | 0.02826     | 0.01171     | 0.0297      | 0.0116      | 0.2202    |
| Protease Ratio ds/dn                       | 6.123       | 7.521       | 7.196       | 5.265       | 0.3129    |

<sup>a</sup>1999 samples: LTR (n = 21), env (n = 18), and pr (n = 20).

<sup>b</sup>2004 samples: LTR (n = 37), env (n = 32), and pr (n = 31).

<sup>c</sup>p-values < 0.05 were considered statistically significant.

**Table 2. Frequency of Known Mutations/Polymorphisms Detected in HIV Protease from ARV Drug-Naive Women**

<table>
<thead>
<tr>
<th>Mutations</th>
<th>Number of strains</th>
<th>Frequency of mutation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>L10V</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>L10I</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>K20R</td>
<td>11</td>
<td>21.6</td>
</tr>
<tr>
<td>M36I</td>
<td>38</td>
<td>74.5</td>
</tr>
<tr>
<td>M36V</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>M36L</td>
<td>2</td>
<td>3.9</td>
</tr>
<tr>
<td>L63P</td>
<td>14</td>
<td>27.5</td>
</tr>
<tr>
<td>L63A</td>
<td>2</td>
<td>3.9</td>
</tr>
<tr>
<td>L63S</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>L63V</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>A71T</td>
<td>2</td>
<td>3.9</td>
</tr>
<tr>
<td>V77I</td>
<td>8</td>
<td>15.7</td>
</tr>
<tr>
<td>V77L</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>I93L</td>
<td>48</td>
<td>94.1</td>
</tr>
</tbody>
</table>
ononymous and nonsynonymous substitutions may therefore provide information on the degree of selection operating on the virus. Both in env and pr, the number of synonymous substitutions increased between 1999 and 2004. Nonsynonymous substitutions also increased in env, indicating that higher variability in this region of env may be caused by the evolutionary force of genetic drift in addition to external selective pressure. An interesting finding of the present study is the higher synonymous and nonsynonymous diversity found within the 2004 sequences as compared to the 1999 sequences. Moreover, median genetic distances were also higher for the 2004 sequences. Although we cannot exclude that differences observed are due to small sample size, it can be hypothesized that the higher heterogeneity of the 2004 viruses may be due to both (1) the introduction of new viruses in Mozambique between 1999 and 2004 as well as (2) the diversification of the viruses introduced prior to 1999. Whether this diversification affects the transmissibility or virulence of subtype C viruses remains to be elucidated. It has been suggested that the genetic bottlenecks created by the transmission of few clones of HIV-1 and pressure from the immune system could reduce the overall fitness of the virus. Furthermore, with the dramatic global spread of subtype C, the question has been raised as to whether this dominance is related to an attenuation of virulence, but this has yet to be investigated.

Primary resistance mutations to protease inhibitors were not found in either the 1999 or 2004 sequences. Nevertheless, a high prevalence of secondary resistance mutations was observed in our sequences, predominantly the M36I and I93L mutations. Although the prevalence of polymorphisms is higher than that described for subtype B viruses, these results are consistent with the high prevalence described in two studies conducted in Mozambique and with other studies performed on non-B clades. The implications of a high prevalence of secondary resistance mutations in subtype C are not known, although the mutation at M36 in the B clade has been associated with greater risk of virological failure and with the appearance of the major resistance mutation L90M.

The prediction of CCR5 or CXCR4 receptor usage based on the net charge of the V3 loop and the presence of the GPGQ crown indicated that most viruses in this study potentially used CCR5, with 13% potentially displaying X4 or mixed R5X4 usage. Little is known in Africa regarding CCR5 and CXCR4 usage. Little is known in Africa regarding CCR5 and CXCR4 usage as a reflection of disease progression. It is generally accepted that viruses present in an individual early in HIV-1 infection are predominantly R5, but the timing of the R5-X4 switch for subtype C viruses is unclear. Nevertheless, as described by Coetzer et al., our results show that CXCR4 usage is not a rare event in subtype C viruses as previously suggested. Unfortunately, CD4+ T cell counts were not available for the samples analyzed and consequently we were unable to assess correlations between CXCR4 usage and disease stage.

In conclusion, this study describes the genetic diversity, molecular evolution, and epidemiological patterns of HIV-1 spread in women from a rural area of southern Mozambique. As implementation of HAART has begun in this area, the description of drug resistance polymorphisms in antiretroviral drug-naive women will be relevant to future evaluations of antiretroviral therapy programs.

SEQUENCE DATA

The GenBank accession numbers of the sequences reported in this paper are EF407648–EF407665 and EF407667–EF407809. The GenBank accession numbers of the reference sequences from neighboring countries used in the phylogenetic trees are AF023427, AF023431, AF127568, AF023430, AF096778, AF096780, AF096782, U63536, U63539, AY1452654, AY196734, AY196733, AY196732, AY452658, AY162225, AY290029, AY162224, AF239628, AF239638, AF239633, AY239654, AF254734, AF254686, AF254723, AF254711, AB192571, AF102218, AF102202, AB191674, AB191676, AB191660, AB191679, U08455, U51292, AM076841, AM076843, AM076847, and AM076846.

ACKNOWLEDGMENTS

The authors are grateful to all the women enrolled in the study and for the continued dedication of VCT, field, clinic, and data management staff at the Centro de Investigación en Saúde de Manhiça, Mozambique. This study was supported by Grant SAFL05845 from the Spanish Ministry of Education and Science and a grant from the Banco de Bilbao Vizcaya Argentaria Foundation (Grant BBVA 02-0). Financial support was also provided by the Spanish Fondo de Investigación Sanitaria (FIS01/1236). The “Centro de Investigación en Saúde de Manhiça” receives core funding from the Spanish Agency for International Cooperation and the VCT center is supported by Generalitat de Catalunya. M.L. was supported by a grant from the IDIBAPS. Work at irisi-Caixa was supported by Spanish Ministry of Education and Science project BFU2006-01066/BMC and FIPSE project 36549/06.

REFERENCES

HIV-1 SUBTYPE C IN MOZAMBIQUE


45. Morris L, Cilliers T, Bredell H, Phoswa M, and Martin DJ: CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res Hum Retroviruses 2001;17:697–701.


Address reprint requests to:

Denise Naniche
Barcelona Center for International Health (CRESIB)
IDIBAPS/Hospital Clinic
Villarroel, 170 Barcelona, E-08036 Spain

E-mail: dsuzanne@clinic.ub.es